SOLIRIS (eculizumab): The first treatment specifically approved for PNH

Financial Assistance for SOLIRIS Patients

OneSource can help you find alternate funding

Financial Assistance for SOLIRIS PatientsIf your own insurance does not cover SOLIRIS® (eculizumab), or if you do not have insurance, your OneSource™ Case Manager may be able to help by providing information on finding alternate funding.

  • The National Organization for Rare Diseases (NORD) has established a PNH Foundation to help patients with out-of-pocket expenses such as insurance premiums or co-payments related to their PNH treatment
     
  • The Alexion COMPLEMENT Foundation is available to help qualified U.S. patients who are uninsured (or who cannot access SOLIRIS by other means) and are in need of treatment

Patient Financial Assistance programs such as these may cover all or part of the cost. Your OneSource Case Manager will assist in finding and working with these organizations, if needed.

Next: OneSource Materials to Download

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.

Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.